111 Inc. American Depositary Shares (YI)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable moats, honest stewards, and a margin of safety. 111 Inc. runs an integrated online and offline healthcare platform in China, with B2C and B2B distribution and related services. Medical distribution is necessary, but it is competitive and often low-margin. In fiscal Q2 2026, the company reported revenue of $2.3B, net income of -$39.1M, and a -1.70% margin. Those are filed figures, and they show scale without profit. Trailing free cash flow is -$39.7M, which is a -70.1% FCF yield against the $56.6M market cap at the 2026-10-13 close. FairStock calculations show a P/E of -1.73, ROE of -14.84%, ROCE of -0.62%, and debt-to-equity of 1.51. The FairStock Score is 25/100, the Piotroski F-Score is 4/9, and the Altman Z-Score is 5.50. The Lynch category is none because only 0 years of filed results are available and 3 are needed. The stock trades at $3.10, far below its 52-week high of $11.17, but a falling price is not the same as value. The business has scale but no demonstrated earning power or cash generation. Until free cash flow turns positive and margins improve, this looks speculative, not a Graham bargain.

In plain English: 111 Inc. runs an online and offline healthcare platform in China, selling medicines and related services to businesses and consumers. The business looks weak: it lost money in its latest reported quarter, burned cash, and carries meaningful debt. At $3.10, the price may look low, but versus its losses and cash burn it does not look clearly cheap; the numbers point to a struggling company rather than a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer